-
Limitations of the updated EULAR recommendations for osteoarthritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-18 Marius Henriksen
-
Evidence-Based Guideline for the management of osteoporosis in men Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-14 Nicholas R. Fuggle, Charlotte Beaudart, Olivier Bruyère, Bo Abrahamsen, Nasser Al-Daghri, Nansa Burlet, Manju Chandran, Mario M. Rosa, Bernard Cortet, Céline Demonceau, Willard Dere, Philippe Halbout, Mickaël Hiligsmann, John A. Kanis, Jean-Marc Kaufman, Andreas Kurth, Olivier Lamy, Andrea Laslop, Stefania Maggi, Radmila Matijevic, Eugene McCloskey, Ali Mobasheri, Maria C. Prieto Yerro, Régis P. Radermecker
-
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-12 Chio Yokose, Natalie McCormick, Abhishek Abhishek, Nicola Dalbeth, Tristan Pascart, Frédéric Lioté, Angelo Gaffo, John FitzGerald, Robert Terkeltaub, Meghan E. Sise, James L. Januzzi, Deborah J. Wexler, Hyon K. Choi
-
A nosology of immune diseases from deep immunophenotyping Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-11 Michael F. McDermott
-
All fibroblasts are equal, but some are more equal than others Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-11 Chrissy Bolton, Adam P. Croft
-
TYK2: an emerging therapeutic target in rheumatic disease Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-11 Eric Morand, Joseph F. Merola, Yoshiya Tanaka, Dafna Gladman, Roy Fleischmann
-
APOE in fat pad and synovium contributes to knee OA Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-07 Robert Phillips
New research has identified apolipoprotein E expressed by fibroblasts and macrophages in the infrapatellar fat pad and synovium as a pathogenetic mediator and potential therapeutic target in knee osteoarthritis.
-
Immunogenic Xist ribonucleoproteins drive sex-biased autoimmunity Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-07 Jessica McHugh
Ribonucleoprotein complexes containing Xist, a long non-coding RNA involved in X chromosome inactivation, are immunogenic and promote autoimmune responses.
-
Eosinophils regulate bone remodelling Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-07 Sarah Onuora
Results of a new study indicate that eosinophils have a role in maintaining bone homeostasis through their inhibitory effects on bone-resorbing osteoclasts.
-
Genetically transitional disease: conceptual understanding and applicability to rheumatic disease Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-02-28 Timothy B. Niewold, Ivona Aksentijevich, Peter D. Gorevic, Greg Gibson, Qingping Yao
-
Targeting NP cell senescence in IVDD Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-02-26 Rebecca Kelsey
Intervertebral disc degeneration (IVDD) is responsible for about 40% of cases of low back pain, the leading cause of disability worldwide. Researchers in China report on a mechanism of IVDD progression whereby aberrant genomic DNA damage promotes senescence of nucleus pulposus (NP) cells, revealing a potential target that could improve IVDD outcomes. Intervertebral discs (IVDs) are avascular fibrocartilaginous
-
The therapeutic potential of immunoengineering for systemic autoimmunity Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-02-21 David A. McBride, Ryan M. Jones, Nunzio Bottini, Nisarg J. Shah
-
A critical view of WHO guidelines on management of low back pain Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-02-14 Mohamad Bittar, Atul Deodhar
The World Health Organization (WHO) has published new guidelines for the non-surgical management of chronic primary low back pain in adults in primary and community care settings. Although the guidelines are commendable, they lack guidance on when to suspect and how to avoid missing important secondary causes of back pain.
-
ZEB2 promotes formation of age-related B cells Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-02-08 Robert Phillips
Age-related B cells (ABCs) have pathogenic roles in autoimmune diseases. Research has now identified ZEB2 as the transcription factor that mediates differentiation into ABCs.
-
GWAS data help unravel Dupuytren disease Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-02-08 Sarah Onuora
A meta-analysis of data from six genome-wide association study cohorts implicates several signalling pathways, including Hedgehog and Notch signalling, in Dupuytren disease.
-
Deep learning in rheumatological image interpretation Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-02-08 Berend C. Stoel, Marius Staring, Monique Reijnierse, Annette H. M. van der Helm-van Mil
-
Sodium channel Nav1.7 regulates chondrocyte biology and OA progression Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-02-07 Jessica McHugh
The voltage-gated sodium channel Nav1.7 is expressed on chondrocytes, regulates chondrocyte biology and osteoarthritis progression, and is a promising dual target for modifying disease while providing pain relief in osteoarthritis.
-
Treatment of non-systemic juvenile idiopathic arthritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-02-06 Susan Shenoi, Gerd Horneff, Amita Aggarwal, Angelo Ravelli
In the past two decades, the treatment of juvenile idiopathic arthritis (JIA) has evolved markedly, owing to the availability of a growing number of novel, potent and relatively safe therapeutic agents and the shift of management strategies towards early achievement of disease remission. However, JIA encompasses a heterogeneous group of diseases that require distinct treatment approaches. Furthermore
-
The gut microbiome in systemic lupus erythematosus: lessons from rheumatic fever Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-02-06 Gregg J. Silverman, Doua F. Azzouz, Nicolas Gisch, Abhimanyu Amarnani
-
Factors identified that predict resolution of subclinical synovitis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-02-05 Jessica McHugh
New findings provide insight into the natural history of subclinical synovitis, a reported predictor of the development of rheumatoid arthritis, and identify various factors associated with its reversal.
-
Difficult-to-treat psoriatic arthritis: moving out of the rheumatoid arthritis shadow Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-26 Stefan Siebert, Helena Marzo-Ortega
As in rheumatoid arthritis, achieving low disease activity or remission in psoriatic arthritis (PsA) remains a challenge and unmet need for many individuals. However, the complex pathogenesis, heterogeneity and varied tissue involvement in PsA mean that dedicated definitions and novel solutions are required for difficult-to-treat disease.
-
Is cell therapy no better than steroid injection? Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-25 Scott A. Rodeo
New findings suggest that current cell therapy approaches are not superior to a simple corticosteroid injection for the treatment of osteoarthritis, calling into question the role of existing cell therapies and highlighting the need for further research and development in this field.
-
Immune tolerance of citrullinated peptides Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-23 Ranjeny Thomas, William H. Robinson
Re-establishing tolerance to autoantigens is an important aim for the treatment of rheumatoid arthritis (RA). Immunization of HLA-DR4 transgenic mice with citrullinated self-antigens can induce immune tolerance, which suggests that such antigens could have a therapeutic role in anti-citrullinated peptide antibody-positive RA.
-
Engineering approaches for RNA-based and cell-based osteoarthritis therapies Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-22 Carlisle R. DeJulius, Bonnie L. Walton, Juan M. Colazo, Richard d’Arcy, Nora Francini, Jonathan M. Brunger, Craig L. Duvall
-
Raynaud phenomenon: from GWAS to drug repurposing Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-16 Ariane L. Herrick, Gisela Orozco
The identification of novel risk variants in the largest genome-wide association study of Raynaud phenomenon to date provides insights into the pathophysiology of the condition, including the potential role for α2A-adrenoceptors, and suggests opportunities for drug repurposing.
-
Proposals for the rheumatological use of JAK inhibitors Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-12 Francesco Ciccia, Roberto Caporali
-
Manipulating tryptophan metabolism in arthritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-12 Robert Phillips
New research has shown that tryptophan metabolism is altered in patients with rheumatoid arthritis, and that correction of this metabolic alteration has a protective effect against collagen-antibody-induced arthritis in mice.
-
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-12 Zoltán Szekanecz, Maya H. Buch, Christina Charles-Schoeman, James Galloway, George A. Karpouzas, Lars Erik Kristensen, Steven R. Ytterberg, Attila Hamar, Roy Fleischmann
-
S100A4 inhibition targets fibrosis in SSc Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-11 Jessica McHugh
New findings suggest that targeting the DAMP protein S100A4 could mitigate both inflammatory and fibrotic pathways in systemic sclerosis.
-
B cells guide rituximab use in AAV remission Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-11 Sarah Onuora
In patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in sustained remission, reinfusion with rituximab after B cell repopulation resulted in fewer clinical relapses than did reinfusion following serological ANCA flare.
-
Recent advances and evolving concepts in Still’s disease Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-11 Piero Ruscitti, Luca Cantarini, Peter A. Nigrovic, Dennis McGonagle, Roberto Giacomelli
-
Exploring the latest advances in axial spondyloarthritis management Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-08 Diego Benavent, Victoria Navarro-Compán
Studies published in 2023 emphasize the long-term efficacy and safety of novel therapeutics for both radiographic and non-radiographic axial spondyloarthritis (axSpA) and provide a consensus definition of ‘early axSpA’ for use in research studies.
-
The rise of precision cellular therapies Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-08 Maximilian F. Konig
-
Advances in the treatment of polymyalgia rheumatica and giant cell arteritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-08 Lindsay Lally, Robert Spiera
Research published in 2023 has demonstrated the efficacy of sarilumab for IL-6 blockade in polymyalgia rheumatica and of secukinumab for IL-17 blockade in giant cell arteritis (GCA). Furthermore, preliminary results with human monocyte-derived suppressive cells suggest the potential of cellular therapeutics for the treatment of GCA.
-
Large language models: rheumatologists’ newest colleagues? Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-01-04 Vincenzo Venerito, Latika Gupta
In 2023, large language models demonstrated potential for use in rheumatology to accurately suggest diagnoses and provide empathetic patient education. However, the propensity of this technology to generate misleading information continues to pose risks. Balancing innovation with physician guidance is essential.
-
Epidemiology of Sjögren syndrome Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-12-18 Maxime Beydon, Sara McCoy, Yann Nguyen, Takayuki Sumida, Xavier Mariette, Raphaèle Seror
-
Emerging therapeutic options for refractory gout Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-12-15 Kanon Jatuworapruk, Worawit Louthrenoo
For individuals with gout, the treatment options beyond conventional urate-lowering therapies are expanding. Notable advancements in 2023 include developments in uricase therapy, new xanthine oxidase inhibitors, and a class of medications that offer dual benefits for the control of type 2 diabetes mellitus and gout.
-
New genes, pathways and therapeutic targets in autoinflammatory diseases Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-12-14 Riccardo Papa, Marco Gattorno
Studies in 2023 have described eight new monogenic autoinflammatory diseases and their accompanying disease-causing mutations, uncovering clinical phenotypes, pathogenic mechanisms and therapeutic targets. Researchers have identified autoinflammatory pathways linked to mitochondrial dysfunction or overactivation of SRC family kinases.
-
Biological and clinical roles of IL-18 in inflammatory diseases Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-12-11 Emily Landy, Hallie Carol, Aaron Ring, Scott Canna
-
Nanohybrid therapy hits multiple arthritis targets Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-12-07 Robert Phillips
A novel combination of ceria nanoparticles and mesenchymal stem cell nanovesicles modified both inflammation and autoimmunity in a mouse model of arthritis.
-
Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-12-06 Xin Lu, Qinglin Peng, Guochun Wang
-
Profiling joint tissues at single-cell resolution: advances and insights Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-12-06 Akshay Pandey, Nidhi Bhutani
-
Primary care rheumatology: towards sustainable development in health Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-12-05 Debashish Danda
Globally, rheumatic musculoskeletal diseases constitute the most common causes of disability, related morbidity and economic loss worldwide. A shortage of rheumatologists warrants education of primary care doctors in primary care rheumatology, public awareness initiatives and advocacy for rheumatic musculoskeletal health.
-
Shifting the SLE management paradigm: challenges and implications Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-12-05 Jacob J. E. Koopman, Karen H. Costenbader
-
Multi-omics reveals distinct MPA subtypes Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-12-01 Sarah Onuora
Using multi-omics analyses, researchers have identified two distinct immunological phenotypes of microscopic polyangiitis, which could inform prognosis and personalized treatment.
-
Targeted NOD2 sequencing uncovers JIA misdiagnosis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-11-29 Sarah Onuora
New findings support the use of targeted next-generation sequencing of NOD2 to reassess the diagnosis of juvenile idiopathic arthritis in patients with signs and symptoms suggestive of Blau syndrome.
-
Single-cell atlas unveils the diversity of RA synovial tissue Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-11-29 Jessica McHugh
Researchers have conducted a comprehensive single-cell analysis of synovial tissue in rheumatoid arthritis, providing insights into the heterogeneity of the disease and informing future treatment strategies.
-
Methotrexate improves pain in hand OA Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-11-10 Jessica McHugh
Methotrexate reduces pain and stiffness in hand osteoarthritis with synovitis, according to the results of a new randomized controlled trial.
-
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-11-09 Alexander G. S. Oldroyd, Jeffrey P. Callen, Hector Chinoy, Lorinda Chung, David Fiorentino, Patrick Gordon, Pedro M. Machado, Neil McHugh, Albert Selva-O’Callaghan, Jens Schmidt, Sarah L. Tansley, Ruth Ann Vleugels, Victoria P. Werth, Rohit Aggarwal
-
Treatment of systemic juvenile idiopathic arthritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-11-03 Claas H. Hinze, Dirk Foell, Christoph Kessel
-
Predominant ligament-centric soft-tissue involvement differentiates axial psoriatic arthritis from ankylosing spondylitis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-11-02 Dennis McGonagle, Paula David, Tom Macleod, Abdulla Watad
-
Immune mechanisms of depression in rheumatoid arthritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-11-03 James Brock, Neil Basu, Johannes C. M. Schlachetzki, Georg Schett, Iain B. McInnes, Jonathan Cavanagh
-
Systemic sclerosis interstitial lung disease: unmet needs and potential solutions Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-11-03 Vasiliki Liakouli, Antonio Ciancio, Francesco Del Galdo, Roberto Giacomelli, Francesco Ciccia
-
l-arginine inhibits arthritis and bone loss by reprogramming osteoclast metabolism Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-11-02 Sarah Onuora
New research shows that the amino acid l-arginine ameliorates arthritis and inhibits inflammatory bone loss by altering energy metabolism in osteoclasts.
-
25 years of biologic DMARDs in rheumatology Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-11-02 Marc Feldmann, Ravinder N. Maini, Enrique R. Soriano, Vibeke Strand, Tsutomu Takeuchi
-
Dual inhibitor targets fibroblast metabolism in RA Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-10-30 Jessica McHugh
Dual inhibition of glycolysis and glutaminolysis in fibroblast-like synoviocytes with a compound called c28MS shows promise in a mouse model of rheumatoid arthritis
-
Maximizing the success of biosimilar implementation Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-10-30 Rieke Alten, Max Weinbrecht-Mischkewitz
Biosimilars have an important place in the treatment of rheumatic conditions. The non-inferiority of biosimilars to bio-originators is ensured, but full and effective clinical adoption of these agents nonetheless requires consideration of several important issues, including the need for shared decision-making and a potential nocebo effect.
-
Enhancer sequence identified as target in SLE Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-10-18 Robert Phillips
Chromatin accessibility of an enhancer that regulates the expression of a disease-associated microRNA is affected in monocytes from patients with systemic lupus erythematosus, highlighting this enhancer as a potential therapeutic target.
-
Collagen-binding antibody prevents arthritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-10-17 Sarah Onuora
New research shows that a recombinant antibody that binds type II collagen protects against the development of arthritis in mice by blocking neutrophil recruitment.
-
Are TNF inhibitors still the agent of choice for RA? Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2023-10-12 Peter C. Taylor
Since entering the clinic 25 years ago, biologic TNF inhibitors have transformed the outlook for people with rheumatoid arthritis and set the standard for all other targeted therapies. Despite changes to the therapeutic landscape, TNF inhibitors look set to remain an important treatment option for the foreseeable future.